TB-500 and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

What Is TB-500 and Why Are Patients Combining It with Rosuvastatin?

TB-500 is a synthetic, 17-amino-acid peptide that corresponds to the active fragment of thymosin beta-4, specifically the sequence Ac-LKKTETQ (sometimes further refined to the tetrapeptide Ac-SDKP). Thymosin beta-4 itself is a 43-amino-acid, G-actin-sequestering protein expressed in nearly every nucleated mammalian cell. The isolated fragment retains the tissue-repair and angiogenic properties of the full-length protein. Goldstein AL et al., Ann N Y Acad Sci, 2012 described its role in cardiac repair and wound healing.

Patients who take rosuvastatin, typically for primary or secondary cardiovascular prevention, are also among the demographics most interested in peptide therapies for recovery after orthopedic surgery, sports injuries, or cardiac events. That clinical overlap makes the combination more common in practice than many physicians expect.

How TB-500 Works at the Cellular Level

Tβ4 binds monomeric G-actin with a 1:1 stoichiometry and a Kd of approximately 0.5 µM, preventing actin polymerization and thereby altering cytoskeletal dynamics in migrating endothelial cells and myofibroblasts. This mechanism was characterized by Safer D et al. In J Biol Chem (1991). The Ac-SDKP tetrapeptide released by prolyl oligopeptidase further inhibits fibrosis by suppressing TGF-β1-driven collagen synthesis in cardiac and renal tissues. Peng H et al., Hypertension (2001) documented anti-fibrotic Ac-SDKP effects in a rat infarction model.

Why Rosuvastatin Patients Seek Peptide Therapies

Post-myocardial infarction and post-bypass patients are frequently prescribed high-intensity rosuvastatin (20-40 mg daily per the 2018 ACC/AHA Cholesterol Guideline) and are simultaneously interested in adjunctive repair strategies. The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol is available here. Some sports-medicine clinicians also prescribe or recommend compounded Tβ4 off-label for tendon and ligament injuries, often in patients who happen to be on statin therapy for metabolic syndrome.

Rosuvastatin Pharmacokinetics: The OATP Pathway Matters Most

Rosuvastatin's interaction profile differs substantially from lipophilic statins such as simvastatin or atorvastatin. Simvastatin undergoes extensive CYP3A4 first-pass metabolism; rosuvastatin does not. Approximately 90% of rosuvastatin is excreted unchanged in feces, and hepatic uptake depends almost entirely on OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) transporters, with BCRP (ABCG2) governing intestinal and biliary efflux. The FDA-approved rosuvastatin (Crestor) prescribing information details this pharmacokinetic profile.

Clinically Relevant Rosuvastatin Interactions

Because OATP1B1/1B3 is the rate-limiting step in rosuvastatin hepatic clearance, any co-administered agent that inhibits these transporters raises plasma rosuvastatin exposure and, consequently, myopathy risk. Classic inhibitors include cyclosporine (contraindicated: 7-fold AUC increase), gemfibrozil (2-fold AUC increase), and atazanavir/ritonavir. FDA Drug Interactions Table for rosuvastatin summarizes these magnitude changes.

The FDA label for rosuvastatin caps the daily dose at 10 mg when combined with cyclosporine, at 20 mg when combined with gemfibrozil, and at 10 mg with atazanavir plus ritonavir. These dose caps are hard limits, not suggestions.

SLCO1B1 Genetic Polymorphisms and Baseline Risk

Before evaluating any new co-medication, the clinician should consider the patient's SLCO1B1 genotype. The c.521T>C polymorphism (rs4149056), present in approximately 15-20% of Europeans and 2-3% of East Asians, raises rosuvastatin AUC by roughly 65% at steady state. CPIC Guideline for statins and SLCO1B1/ABCG2 (2022 update) is accessible via PharmGKB. Patients carrying this variant already sit closer to the myopathy threshold before any additional agent is introduced.

Does TB-500 Affect OATP1B1, BCRP, or CYP Enzymes?

This is the central pharmacokinetic question. The direct answer: no published human or in vitro transporter study has tested Tβ4 or Ac-SDKP against OATP1B1, OATP1B3, BCRP, or any CYP isoform in a head-to-head assay.

Why Peptides Are Unlikely to Be OATP Inhibitors

Small peptides cleared by proteolysis (aminopeptidases, dipeptidyl peptidases, prolyl oligopeptidase) do not typically achieve the sustained plasma concentrations or lipophilicity required to competitively inhibit hepatic uptake transporters. Tβ4's LogP is negative (hydrophilic), its plasma half-life in rodents is less than 2 hours after SC injection, and peak concentrations after compounded human doses (2-5 mg SC) are unlikely to reach the IC50 of even modest OATP inhibitors. No in vitro FDA-guidance transporter panel (the seven standard transporters: P-gp, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3) has been published for this peptide. FDA Guidance for Industry: In Vitro Drug Interaction Studies (2020) outlines the standard expectation.

CYP Enzyme Involvement

Rosuvastatin is minimally metabolized by CYP2C9 (approximately 10% conversion to N-desmethyl rosuvastatin), but this pathway is not the primary determinant of statin exposure or toxicity. Tβ4 has no known CYP enzyme substrate, inhibitor, or inducer activity. Peptide bonds are hydrolyzed by non-CYP protease pathways. The combination carries essentially no predicted pharmacokinetic interaction through CYP channels.

Pharmacodynamic Interaction: Where Caution Is Warranted

Even when two drugs do not share a metabolic pathway, they may converge on the same biological endpoint. With TB-500 and rosuvastatin, three pharmacodynamic overlap zones are worth examining.

Skeletal Muscle: Statin Myopathy and Tβ4 Actin Dynamics

Statins inhibit mevalonate synthesis, reducing not only cholesterol but also geranylgeranyl pyrophosphate and farnesyl pyrophosphate. Depletion of these isoprenoids impairs mitochondrial function, disrupts small GTPase signaling (RhoA, Rac1), and may destabilize the sarcolemma. Vaklavas C et al., Atherosclerosis (2009) reviewed the mitochondrial pathway of statin myopathy.

Tβ4 modulates actin dynamics in skeletal muscle satellite cells and may promote muscle repair after eccentric exercise injury. At face value this sounds protective. The concern is more subtle: if Tβ4 signals through Rac1 or RhoA (both actin-regulatory GTPases whose prenylation is reduced by statins), the net effect on muscle fiber integrity from the combination is genuinely unpredictable. No controlled study has examined this.

Clinically, the practical instruction is: if a patient on rosuvastatin develops new-onset myalgia within 4-8 weeks of starting TB-500, obtain a serum CK promptly rather than attributing symptoms to peptide injection-site soreness.

Vascular Endothelium: Potential Combination or Interference?

Both rosuvastatin and Tβ4 promote endothelial nitric oxide synthase (eNOS) activity and angiogenesis. Rosuvastatin's pleiotropic eNOS upregulation is well established: in the JUPITER trial (N=17,802, median follow-up 1.9 years), rosuvastatin 20 mg reduced major cardiovascular events by 44% versus placebo in patients with hsCRP above 2 mg/L, partly attributed to anti-inflammatory pleiotropic effects. Ridker PM et al., N Engl J Med (2008). Tβ4's angiogenic role in a mouse myocardial infarction model was shown by Bock-Marquette I et al., Nature (2004), where Tβ4 pretreatment increased coronary vessel density and reduced infarct size by approximately 30%. Bock-Marquette I et al., Nature (2004).

Whether additive eNOS stimulation translates to clinically meaningful benefit or to hypotension in susceptible patients is not known. Blood pressure monitoring is reasonable.

Anti-Fibrotic Pathways and TGF-β

Ac-SDKP inhibits TGF-β1-mediated fibrosis. Statins also reduce TGF-β1 expression in cardiac tissue, as demonstrated in several small human trials. Dual inhibition of TGF-β1 does not carry an established adverse-effect profile in humans but could theoretically alter wound-healing responses in post-surgical patients. Surgeons should be informed when a patient is taking both agents.

What the Clinical DDI Databases Say

Lexicomp, Micromedex, and Drugs.com do not list a TB-500/rosuvastatin interaction entry. This is expected: because Tβ4 has no FDA approval and has undergone no formal NDA pharmacokinetic studies, no interaction rating exists. The absence of a rating is not evidence of safety; it reflects evidence absence.

The HealthRX clinical team uses the following four-factor framework when evaluating any unapproved peptide co-administered with a statin:

1. Transporter liability. Does the peptide inhibit OATP1B1/1B3 or BCRP? If in vitro data are absent, assume theoretical risk proportional to LogP and plasma half-life. For Tβ4: low theoretical risk.
2. Shared end-organ. Do both agents affect the same tissue (muscle, liver, endothelium)? For Tβ4 plus rosuvastatin: yes, skeletal muscle and vascular endothelium are shared targets. Intermediate pharmacodynamic concern.
3. Isoprenoid pathway crosstalk. Does the peptide depend on prenylated GTPases for its mechanism? For Tβ4: possible dependence on Rac1, which is depleted by statins. Flag for monitoring.
4. Patient-level vulnerability. SLCO1B1 c.521T>C carrier, CKD (eGFR <30 mL/min/1.73m²), hypothyroidism, age over 75, high-dose rosuvastatin (40 mg). If two or more risk factors are present, consider reducing rosuvastatin to the lowest effective dose before adding any uncharacterized peptide.

Monitoring Protocol for Patients Using Both Agents

Baseline Assessments Before Starting TB-500

• Serum creatine kinase (CK): if above 5x ULN at baseline, defer TB-500 until the cause is identified.
• Comprehensive metabolic panel (ALT, AST, creatinine, eGFR).
• Thyroid-stimulating hormone: hypothyroidism elevates myopathy risk independently.
• Document current rosuvastatin dose and duration; patients stabilized on rosuvastatin for over 6 months are at lower early myopathy risk than those newly initiated.

On-Treatment Monitoring

Obtain serum CK at 4-6 weeks after starting TB-500. Repeat if any of the following develop: unexplained muscle pain, weakness, brown urine, or disproportionate exercise fatigue. The FDA label defines myopathy as CK above 10x ULN with symptoms. Rhabdomyolysis is defined as myopathy plus serum creatinine elevation or myoglobinuria. If rhabdomyolysis is suspected, withhold rosuvastatin immediately and provide IV hydration. FDA Crestor label, 2010, Section 5.1.

No equivalent FDA monitoring framework exists for TB-500, because it carries no approved labeling.

Injection-Site and General Safety Monitoring for TB-500

Compounded TB-500 is delivered subcutaneously or intramuscularly. Sterility and endotoxin burden depend entirely on the 503A pharmacy's quality controls. The United States Pharmacopeia (USP) Chapter 797 governs compounding standards. Patients should inspect each vial, report fever or injection-site swelling promptly, and use only licensed 503A pharmacies that provide a Certificate of Analysis. USP Chapter 797 overview via the FDA compounding page.

Patient Counseling Points

Patients asking "can I take TB-500 with rosuvastatin?" deserve an honest answer: based on current evidence, the combination is not known to cause a clinically significant pharmacokinetic interaction. Rosuvastatin's plasma exposure is unlikely to change meaningfully because Tβ4 almost certainly does not inhibit OATP1B1 or BCRP at concentrations achieved with compounded doses. The muscle safety signal is the more relevant concern, and it is manageable with standard monitoring.

Three specific points every prescriber should communicate:

• Stop TB-500 and contact your physician the same day if muscle pain develops and is rated 4/10 or higher in intensity, especially if it is not localized to the injection site.
• Rosuvastatin must not be stopped without physician guidance, particularly in patients with established cardiovascular disease, because statin discontinuation is associated with rebound inflammation and increased short-term cardiovascular event risk. Colivicchi F et al., J Am Coll Cardiol (2007) documented excess mortality with statin withdrawal post-ACS.
• TB-500 is not FDA-approved. Any adverse event should be reported to MedWatch (FDA Safety Reporting Portal) and to the dispensing pharmacy.

Special Populations

Patients with Chronic Kidney Disease

Rosuvastatin is renally cleared to a greater extent than most statins. In patients with eGFR <30 mL/min/1.73m², rosuvastatin AUC increases approximately 3-fold. The FDA label recommends a starting dose of 5 mg and a maximum dose of 10 mg in severe CKD. Ac-SDKP is known to reduce renal fibrosis in animal models, which is a theoretically desirable effect in CKD patients, but no human safety data for Tβ4 in CKD exists. Adding TB-500 in a patient with CKD who is already near the rosuvastatin dose ceiling warrants nephrology input.

Post-Cardiac Surgery Patients

This is the population most likely to want both agents simultaneously. Rosuvastatin 20-40 mg is standard post-CABG or post-ACS per current ACC/AHA guidelines. Some integrative cardiology practices administer compounded Tβ4 to accelerate myocardial repair, citing the Bock-Marquette Nature 2004 data. Physicians in this context should confirm that the compounding pharmacy has passed sterility testing and should track CK and hepatic enzymes at 30-day intervals for the first 3 months.

Athletes on Therapeutic-Use Exemptions

TB-500 appears on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). [WADA Prohibited List 2024 is published at wada-ama.org.] Athletes who compete in tested sports and take rosuvastatin for a cardiac indication should be aware that TB-500 use outside an approved TUE constitutes a doping violation, regardless of the drug interaction profile.

Evidence Gaps and Research Priorities

The field needs specific data before any firm interaction conclusion can be drawn:

• A standard FDA in vitro transporter panel (OATP1B1, OATP1B3, BCRP, P-gp) for Tβ4 and Ac-SDKP at physiologically achievable concentrations.
• A pharmacokinetic crossover study measuring rosuvastatin AUC with and without co-administered Tβ4 in healthy volunteers.
• Mechanistic work clarifying whether Tβ4's actin effects in skeletal muscle are Rac1-dependent and therefore potentially altered by statin-induced isoprenoid depletion.

Until those studies exist, clinical decisions rest on mechanistic inference rather than direct evidence. The current risk signal is theoretical and probably low for most patients, but that assessment could change with published data.

The JUPITER trial remains the most rigorous outcome dataset for rosuvastatin 20 mg: in 17,802 patients followed for a median of 1.9 years, the myalgia rate was not statistically different from placebo (2.98% vs. 2.71%), but rhabdomyolysis occurred in 0.1% of the rosuvastatin arm. Ridker PM et al., N Engl J Med (2008). Any co-medication that might shift muscle fiber vulnerability even modestly deserves disclosure to the patient.

Patients on rosuvastatin 40 mg daily should obtain a serum CK measurement before starting TB-500 and again at week 6; a CK value above 3x ULN at either time point should prompt a shared decision about whether to continue both agents or pause TB-500 until the CK normalizes.